null - FindTrial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224550

Enrollment

1086

Registered

2019-02-06

Start date

2019-01-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : INN of investigational material : Pembrolizumab, Carboplatin, Paclitaxel, Olaparib, Bevacizumab Therapeutic category code : 42- Antineoplastic agents D

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
efficacy	—

Secondary

Measure	Time frame
safety efficacy	—

Countries

Asia except Japan, Europe, Japan

Outcome results